Clinical and biological features prognostic of survival after relapse or progression of INRGSS stage MS pattern neuroblastoma: A report from the International Neuroblastoma Risk Group (INRG) project

被引:7
作者
Campbell, Kevin [1 ,2 ]
Kao, Pei-Chi [1 ,2 ]
Naranjo, Arlene [3 ]
Kamijo, Takehiko [4 ]
Ramanujachar, Ramya [5 ]
London, Wendy B. [1 ,2 ]
DuBois, Steven G. [1 ,2 ]
机构
[1] Dana Farber Boston Childrens Canc & Blood Disorde, Boston, MA USA
[2] Harvard Med Sch, Boston, MA 02115 USA
[3] Univ Florida, Childrens Oncol Grp, Dept Biostat, Stat & Data Ctr, Gainesville, FL USA
[4] Saitama Canc Ctr, Res Inst Clin Oncol, Saitama, Japan
[5] Univ Hosp Southampton NHS Fdn Trust, Paediat Oncol, Southampton, Hants, England
关键词
INRGSS stage MS; neuroblastoma; prognosis; relapse; CLASSIFICATION-SYSTEM; DIAGNOSIS; CRITERIA; INFANTS;
D O I
10.1002/pbc.30054
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
Background Outcomes for patients with INRGSS metastatic special (MS) metastatic pattern neuroblastoma at initial diagnosis are well described. Prognosis after an initial event (relapse, progression, secondary malignancy) is unclear. Methods We investigated characteristics of MS pattern neuroblastoma patients in the International Neuroblastoma Risk Group database who subsequently experienced an event. Post-event overall survival (OS) +/- standard error was calculated overall and by diagnosis era: before 2000 versus 2001 or after. Cox models were used to identify factors prognostic of post-event OS. Results Among 209 patients with an event, 88% were less than 365 days old at diagnosis; tumors were MYCN amplified in 24% and diploid in 33%. The median (range) time from diagnosis to first event was 8.16 months (7 days to 11.24 years). Of 96 patients with known relapse/progression pattern, 75% were metastatic or primary plus metastatic. Five-year post-event OS was 53% +/- 3.6% and was higher for 2001 and afterwards (62% +/- 5.0%) compared to before 2001 (44% +/- 4.9%; p = .0046). In patients diagnosed in 2001 and after, older age, Hispanic ethnicity, MYCN amplification, 1p LOH, diploidy, high Mitotic Karyorrhexis Index, high lactate dehydrogenase (LDH), unfavorable histology, and longer time to first event were prognostic of worse post-event OS. Independent adverse prognostic factors on multivariable testing were non-White race, MYCN amplification, and diploidy. Patients diagnosed in and after 2001 have substantially better post-event OS compared to before 2001. In those diagnosed in and after 2001, most well-accepted prognostic factors for OS at diagnosis are also prognostic of post-event OS. Future studies may evaluate strategies to improve outcomes in this rare population.
引用
收藏
页数:11
相关论文
共 21 条
  • [1] Factors associated with recurrence and survival length following relapse in patients with neuroblastoma
    Basta, Nermine O.
    Halliday, Gail C.
    Makin, Guy
    Birch, Jillian
    Feltbower, Richard
    Bown, Nick
    Elliott, Martin
    Moreno, Lucas
    Barone, Giuseppe
    Pearson, Andrew D. J.
    James, Peter W.
    Tweddle, Deborah A.
    McNally, Richard J. Q.
    [J]. BRITISH JOURNAL OF CANCER, 2016, 115 (09) : 1048 - 1057
  • [2] Poverty and Targeted Immunotherapy: Survival in Children's Oncology Group Clinical Trials for High-Risk Neuroblastoma
    Bona, Kira
    Li, Yimei
    Winestone, Lena E.
    Getz, Kelly D.
    Huang, Yuan-Shung
    Fisher, Brian T.
    Desai, Ami, V
    Richardson, Troy
    Hall, Matt
    Naranjo, Arlene
    Henderson, Tara O.
    Aplenc, Richard
    Bagatell, Rochelle
    [J]. JNCI-JOURNAL OF THE NATIONAL CANCER INSTITUTE, 2021, 113 (03): : 282 - 291
  • [3] REVISIONS OF THE INTERNATIONAL CRITERIA FOR NEUROBLASTOMA DIAGNOSIS, STAGING, AND RESPONSE TO TREATMENT
    BRODEUR, GM
    PRITCHARD, J
    BERTHOLD, F
    CARLSEN, NLT
    CASTEL, V
    CASTLEBERRY, RP
    DEBERNARDI, B
    EVANS, AE
    FAVROT, M
    HEDBORG, F
    KANEKO, M
    KEMSHEAD, J
    LAMPERT, F
    LEE, REJ
    LOOK, AT
    PEARSON, ADJ
    PHILIP, T
    ROALD, B
    SAWADA, T
    SEEGER, RC
    TSUCHIDA, Y
    VOUTE, PA
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 1993, 11 (08) : 1466 - 1477
  • [4] INTERNATIONAL CRITERIA FOR DIAGNOSIS, STAGING, AND RESPONSE TO TREATMENT IN PATIENTS WITH NEURO-BLASTOMA
    BRODEUR, GM
    SEEGER, RC
    BARRETT, A
    BERTHOLD, F
    CASTLEBERRY, RP
    DANGIO, G
    DEBERNARDI, B
    EVANS, AE
    FAVROT, M
    FREEMAN, AI
    HAASE, G
    HARTMANN, O
    HAYES, FA
    HELSON, L
    KEMSHEAD, J
    LAMPERT, F
    NINANE, J
    OHKAWA, H
    PHILIP, T
    PINKERTON, CR
    PRITCHARD, J
    SAWADA, T
    SIEGEL, S
    SMITH, EI
    TSUCHIDA, Y
    VOUTE, PA
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 1988, 6 (12) : 1874 - 1881
  • [5] A Review of Infants With Localized Neuroblastoma That Evolve to Stage 4s Disease
    Caroleo, Anna M.
    De Bernardi, Bruno
    Avanzini, Stefano
    Gigliotti, Anna R.
    Muraca, Monica
    Pota, Elvira
    Provenzi, Massimo
    Mazzocco, Katia
    Sementa, Angela R.
    Granata, Claudio
    Sorrentino, Stefania
    [J]. JOURNAL OF PEDIATRIC HEMATOLOGY ONCOLOGY, 2020, 42 (06) : E483 - E487
  • [6] The International Neuroblastoma Risk Group (INRG) Classification System: An INRG Task Force Report
    Cohn, Susan L.
    Pearson, Andrew D. J.
    London, Wendy B.
    Monclair, Tom
    Ambros, Peter F.
    Brodeur, Garrett M.
    Faldum, Andreas
    Hero, Barbara
    Iehara, Tomoko
    Machin, David
    Mosseri, Veronique
    Simon, Thorsten
    Garaventa, Alberto
    Castel, Victoria
    Matthay, Katherine K.
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 2009, 27 (02) : 289 - 297
  • [7] DANGIO GJ, 1971, LANCET, V1, P1046
  • [8] DO INFANTS WITH STAGE IV-S NEURO-BLASTOMA NEED TREATMENT
    EVANS, AE
    BAUM, E
    CHARD, R
    [J]. ARCHIVES OF DISEASE IN CHILDHOOD, 1981, 56 (04) : 271 - 274
  • [9] EVANS AE, 1971, CANCER, V27, P374, DOI 10.1002/1097-0142(197102)27:2<374::AID-CNCR2820270221>3.0.CO
  • [10] 2-G